Stronger Together: Bayesian Evidence from Four Countries Reinforces Early High-Efficacy Treatment in Multiple Sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27661989%3A_____%2F25%3A10003552" target="_blank" >RIV/27661989:_____/25:10003552 - isvavai.cz</a>

Výsledek na webu

<a href="https://journals.sagepub.com/toc/msja/31/3_suppl" target="_blank" >https://journals.sagepub.com/toc/msja/31/3_suppl</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/13524585251358339" target="_blank" >10.1177/13524585251358339</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Stronger Together: Bayesian Evidence from Four Countries Reinforces Early High-Efficacy Treatment in Multiple Sclerosis

Popis výsledku v původním jazyce

This study evaluated the benefit of early initiation of high‑efficacy disease‑modifying therapies (HE‑DMT) in patients with relapsing–remitting multiple sclerosis using data from the Australian MSBase cohort and the Czech national ReMuS registry. Patients initiating their first DMT between 2013–2018 with at least five years of follow‑up were included. After balancing the cohorts using propensity score weighting, early HE‑DMT initiation was associated with a lower risk of relapses, 6‑month confirmed disability worsening, and reaching EDSS 3, alongside a higher probability of disability improvement. Subsequent Bayesian survival modelling incorporating results from prior international registry comparisons confirmed and further refined these findings. The study provides independent and internationally consistent evidence supporting early intensive treatment as an effective strategy in multiple sclerosis management.

Název v anglickém jazyce

Stronger Together: Bayesian Evidence from Four Countries Reinforces Early High-Efficacy Treatment in Multiple Sclerosis

Popis výsledku anglicky

This study evaluated the benefit of early initiation of high‑efficacy disease‑modifying therapies (HE‑DMT) in patients with relapsing–remitting multiple sclerosis using data from the Australian MSBase cohort and the Czech national ReMuS registry. Patients initiating their first DMT between 2013–2018 with at least five years of follow‑up were included. After balancing the cohorts using propensity score weighting, early HE‑DMT initiation was associated with a lower risk of relapses, 6‑month confirmed disability worsening, and reaching EDSS 3, alongside a higher probability of disability improvement. Subsequent Bayesian survival modelling incorporating results from prior international registry comparisons confirmed and further refined these findings. The study provides independent and internationally consistent evidence supporting early intensive treatment as an effective strategy in multiple sclerosis management.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Multiple Sclerosis Journal

ISSN

1352-4585

e-ISSN

1477-0970

Svazek periodika

31

Číslo periodika v rámci svazku

3 Supplement

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

2

Strana od-do

111-112

Kód UT WoS článku

001603659900116

EID výsledku v databázi Scopus

—